|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300076364 |
|
最近更新日期: Date of Last Refreshed on: |
2023-10-07 11:19:34 |
|
注册时间: Date of Registration: |
2023-10-07 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
艾司氯胺酮术前用药对儿童术后行为的影响 |
|
Public title: |
Effects of intranasal esketamine premedication on minimum alveolar concentration of sevoflurane for laryngeal mask airway insertion in children |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
艾司氯胺酮术前用药对儿童术后行为的影响 |
|
Scientific title: |
Effects of intranasal esketamine premedication on minimum alveolar concentration of sevoflurane for laryngeal mask airway insertion in children |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
陈思思 |
研究负责人: |
姚玉笙 |
|
Applicant: |
Chen Sisi |
Study leader: |
Yao Yusheng |
|
申请注册联系人电话: Applicant telephone: |
+86 150 8010 9541 |
研究负责人电话: Study leader's telephone: |
+86 135 5993 9629 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
css@fjmu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
fjslyys@fjmu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
福建省福州市鼓楼区东街134号 |
研究负责人通讯地址: |
福建省福州市鼓楼区东街134号 |
|
Applicant address: |
Fujian Provincial Hospital, 134 East Street, Gulou District, Fuzhou City, Fujian Province |
Study leader's address: |
Fujian Provincial Hospital, 134 East Street, Gulou District, Fuzhou City, Fujian Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
福建省立医院 |
||
|
Applicant's institution: |
Fujian Provincial Hospital |
||
|
研究负责人所在单位: |
福建省立医院 |
||
|
Affiliation of the Leader: |
Fujian Provincial Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦申科研第(K2023-01-003)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
福建省立医院伦理委员会 |
||
|
Name of the ethic committee: |
the Ethics Committee of Fujian Provincial Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-01-18 00:00:00 |
||
|
伦理委员会联系人: |
练发扬 |
||
|
Contact Name of the ethic committee: |
Lian Fayang |
||
|
伦理委员会联系地址: |
福建省福州市鼓楼区东街134号 |
||
|
Contact Address of the ethic committee: |
134 Dong Street, Gulou District, Fuzhou, Fujian |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 591 8821 6023 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
福建省立医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Fujian Provincial Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
福建省福州市鼓楼区东街134号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
134 Dong Street, Gulou District, Fuzhou, Fujian |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
福建省医学创新课题(No. 2022CXA007) |
||||||||||||||||||||||
|
Source(s) of funding: |
the Fujian Medical Innovation Project (No. 2022CXA007) |
||||||||||||||||||||||
|
Target disease: |
Strabismus |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
通过前瞻性、随机、双盲、平行对照试验,研究艾司氯胺酮术前给药对儿童喉罩置入时七氟烷最低肺泡浓度、苏醒期谵妄发生率以及术后负性行为的影响,为优化临床麻醉用药方案提供参考。 |
||||||||||||||||||||||
|
Objectives of Study: |
We conducted this prospective, randomized, double-blind study to verify the hypothesis that intranasal esketamine might decrease the minimum alveolar concentration for laryngeal mask airway insertion of sevoflurane, the incidence of emergence delirium, and postoperative behavior changes in children. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1)ASA分级I或II(2)年龄2–5岁(3)择期行斜视手术 |
||||||||||||||||||||||
|
Inclusion criteria |
1. ASA physical status I or II; 2. Aged 2-5 years; 3. Scheduled for elective strabismus surgery. |
||||||||||||||||||||||
|
排除标准: |
(1)存在困难气道;(2)哮喘病史;(3)急性上呼吸道感染;(4)近期使用镇静剂或镇痛药;(5)精神疾病;(6)BMI>30 kg/m2;(7)对研究药物过敏;(8)患者术前有重大生活变化,如父母离异、父母死亡、搬到新家、换新幼儿园等;(9)其他任何不能参加的理由。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Potentially difficult airway; 2. Asthma; 3. Any sign of upper respiratory infection; 4. Intake of sedative or analgesic medication within 48 hours before surgery; 5. Psychosis; 6. Body mass index > 30 kg/m2; 7. Allergy to study drugs; 8. Major life changes 1 month before the operation, such as the divorce of parents, death of parents, moving to a new home, changing to a new kindergarten, etc.; 9. Any other conditions that precluded study inclusion. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-10-20 00:00:00至 To 2024-09-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2023-10-20 00:00:00 至 To 2024-09-29 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由不参加实验的研究人员根据电脑随机生成数字表对纳入正式研究的受试者按1:1:1的比例进行随机分组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Eligible study participants were randomized 1:1:1 into three groups by an independent statistician using computer-generated random numbers. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
患儿家属、主麻医师、外科医生、数据收集者均对分组不知情。 |
|
Blinding: |
The patients' parents, attending anesthesiologist, surgeon team, and data collection personnel were blinded to the group assignment. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
论文结果包括方案通过联系通讯作者获取。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After publication, the metadata and the study protocol can be accessed upon reasonable request from the corresponding author. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
采用CFR和EDC进行数据采集和管理。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection and Management using CRF and EDC. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |